Faron Pharmaceuticals Oy
OMXH:FARON
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
F
|
Faron Pharmaceuticals Oy
OMXH:FARON
|
FI |
|
B
|
Booking Holdings Inc
F:PCE1
|
US |
Intrinsic Value
The intrinsic value of 
Faron Pharmaceuticals Oy (FARON) under the Base Case is 0.241 EUR per share.
Compared with the current market price of 0.3545 EUR, the stock appears
Overvalued by 32% .
The intrinsic value is calculated using valuation multiples.
Do our valuations actually work? See backtest results .
Cheap or expensive for this stock?
This block shows whether today’s valuation is cheap or expensive compared with the stock’s own history, and what happened after similar valuations in the past.
We compare the gap between the stock’s price and our estimated value over time.
- Undervalued can still be historically expensive. The stock may trade below our estimated value, but usually offer an even bigger discount.
- Overvalued can still be historically cheap. The stock may trade above our estimated value, but usually carry an even higher premium.
Market expectations can differ from our model, which may not fully capture everything affecting the price. That is why some stocks regularly trade above our estimated value and others below it.
The scale and chart show how today’s valuation compares with the past. The cards summarize past returns and waiting times until the stock stopped being cheap or expensive. This can happen because the price changed, our estimated value changed, or both.
Only completed periods are included. These are past results, not forecasts. The usual historical range does not necessarily mean fair value.
Fundamental Analysis
What Faron Pharmaceuticals Oy Does
Faron Pharmaceuticals is a drug development company focused on medicines that change how the immune system behaves in cancer and severe inflammation. Its main work is to discover and test new drug candidates, especially bexmarilimab, an immunotherapy aimed at helping the body’s own defenses attack tumors. The company is not a mass-market drug seller; it is a research-stage biotech trying to turn lab findings into approved medicines.
- Headquarters
- Finland FI
- Employees
- 33
- IPO date
- Nov 17, 2015
Earnings Waterfall
Faron Pharmaceuticals Oy
The intrinsic value for Faron Pharmaceuticals Oy (FARON) under the Base Case is 0.241 EUR.
Compared with the current market price of 0.3545 EUR, the stock appears Overvalued by 32% .
